Clinical Trial: CIRCAdian Rhythm of the IMMune Age IndeX (IMMAX) - A Longitudinal Single-day Experimental Study to Determine the Circadian Influence on the Immune Age Biomarker IMMAX of 50 Participants Aged 20-69.

U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07169721) titled 'CIRCAdian Rhythm of the IMMune Age IndeX (IMMAX) - A Longitudinal Single-day Experimental Study to Determine the Circadian Influence on the Immune Age Biomarker IMMAX of 50 Participants Aged 20-69.' on Sept. 05.

Brief Summary: The goal of this observational study is to evaluate the influence of circadian rhythms on the determination of an individual's immune age. The biomarker IMMAX was calculated for 50 participants aged 20-69 at 8 a.m., 1 p.m. and 6 p.m. on the same day.

Study Start Date: Dec. 01, 2023

Study Type: OBSERVATIONAL

Condition: Condition: Healthy Individuals Without Malignant Diseases or Chronic Inflammatory Diseas...